Open Access Open Access  Restricted Access Subscription or Fee Access

CAR T-Cell Therapy: New Therapeutic Immunotherapy Innovation in Cancer

Rupinder Kaur

Abstract


Immunotherapy is treatment that uses person’s own immune system to fight against cancer. It can
boost or change the working of immune system so that it can find and attack cancer. T-cells are
immune system cells that play very important role in the body’s immune system to fight against the
disease. These cells help the immune system, respond to a disease and directly kill diseased cells.
Immunotherapy drugs are now approved for treatment of multiple cancer types either as first-line

treatment or when standard first-line treatment has failed. The FDA has recently approved the anti-
PD-1 antibody pembrolizumab for the treatment of any unresectable solid tumors.


Full Text:

PDF

References


FDA News Release. FDA approves first cancer treatment for any solid tumor with a specific

genetic feature. Accessed on 30 Oct 2017.

American Society of Clinical Oncology (ASCO) ASCO Annual Meeting 2019: Immunotherapy

for lung cancer, gastrointestinal cancers and targeted therapy for breast cancer. Accessed at

https://www.cancer.net/blog/2019-06/asco-annual-meeting-2019-immunotherapy-lung-cancer-

gastrointestinal-cancers-and-targeted-therapy on December 19, 2019.

Bayer VR, Davis ME, Gordan RA, et al. Chemotherapy and Immunotherapy Guidelines and

Recommendations for Practice. Pittsburgh, PA: Oncology Nursing Society; 2019: 149–89.

National Cancer Institute (NCI). CAR T cells: Engineering patients’ immune cells to treat their

cancers. Available at: http://www.cancer.gov.

Porter DL, Maloney DG. Cytokine release syndrome (CRS). Accessed at

https://www.uptodate.com/contents/cytokine-release-syndrome-crs on April 01, 2021. Last

Revised: April 5, 2021.

Hedge PS, Karanikas V, Evers S. The where, the when and how of immune monitoring for cancer

immunotherapies in the era of checkpoint inhibition. Clin Cancer Res. 2016; 22: 1865–74.

TF Gajewski. The next hurdle in cancer immunotherapy: overcoming the non-T-cell-inflamed

tumor microenvironment. Semin Oncol. 2015; 42: 663–71.

Riddell SR, Sirvastava S. CAR T cell therapy: challenges to bench to bedside efficacy, J

Immunol. 2018, Jan 15; 200(2): 459–68.

Bonifant CL, Jakson HJ, Curran KJ. Toxicity and management in CAR T-cell therapy, 2016; 3.

Han D, Xu Z, Zhuang Y, Qian Q. Current progress in CAR T-cell therapy for hematological

malignancies; J Cancer. 2020; 12(2): 326–34.


Refbacks

  • There are currently no refbacks.